Commerce Bank Takes Position in Zimmer Biomet Holdings, Inc. $ZBH

Commerce Bank acquired a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 12,935 shares of the medical equipment provider's stock, valued at approximately $1,114,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of ZBH. Brighton Jones LLC purchased a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $204,000. Sivia Capital Partners LLC bought a new position in Zimmer Biomet during the second quarter valued at $232,000. United Bank increased its position in Zimmer Biomet by 10.7% in the second quarter. United Bank now owns 11,896 shares of the medical equipment provider's stock worth $1,085,000 after buying an additional 1,153 shares during the last quarter. Federated Hermes Inc. raised its stake in shares of Zimmer Biomet by 129.2% in the second quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider's stock valued at $194,000 after buying an additional 1,202 shares during the period. Finally, Cerity Partners LLC lifted its position in shares of Zimmer Biomet by 93.6% during the 2nd quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider's stock valued at $7,004,000 after buying an additional 37,116 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently weighed in on ZBH. Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a report on Thursday, August 6th. BMO Capital Markets reaffirmed a "market perform" rating and set a $96.00 price objective on shares of Zimmer Biomet in a report on Thursday, August 6th. Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th. Wells Fargo & Company reduced their target price on shares of Zimmer Biomet from $98.00 to $90.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 29th. Finally, Wall Street Zen lowered shares of Zimmer Biomet from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $104.42.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $101.41 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $107.85. The firm has a market cap of $19.34 billion, a PE ratio of 24.67, a price-to-earnings-growth ratio of 2.72 and a beta of 0.45. The business has a 50 day moving average price of $93.40 and a 200-day moving average price of $91.31.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts' consensus estimates of $2.01 by $0.06. The company had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The firm's revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the business posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current year.

Insider Activity at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the company's stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares of the company's stock, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.28% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source